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Abstract
Background: In clinical trials, both unequal randomization design and sequential analyses have
ethical and economic advantages. In the single-stage-design (SSD), however, if the sample size is not
adjusted based on unequal randomization, the power of the trial will decrease, whereas with
sequential analysis the power will always remain constant. Our aim was to compare sequential
boundaries approach with the SSD when the allocation ratio (R) was not equal.
Methods: We evaluated the influence of R, the ratio of the patients in experimental group to the
standard group, on the statistical properties of two-sided tests, including the two-sided single
triangular test (TT), double triangular test (DTT) and SSD by multiple simulations. The average
sample size numbers (ASNs) and power (1-β) were evaluated for all tests.
Results: Our simulation study showed that choosing R = 2 instead of R = 1 increases the sample
size of SSD by 12% and the ASN of the TT and DTT by the same proportion. Moreover, when R
= 2, compared to the adjusted SSD, using the TT or DTT allows to retrieve the well known
reductions of ASN observed when R = 1, compared to SSD. In addition, when R = 2, compared to
SSD, using the TT and DTT allows to obtain smaller reductions of ASN than when R = 1, but
maintains the power of the test to its planned value.
Conclusion: This study indicates that when the allocation ratio is not equal among the treatment
groups, sequential analysis could indeed serve as a compromise between ethicists, economists and
statisticians.
Background
One of the key reasons for using sequential methods,
instead of single-stage design (SSD), in planning clinical
trials is that the expected number of patients is decreased
while maintaining the pre-specified significance level and
power. Sequential designs have become common practice
in interim monitoring of clinical trials because of their
ethical and economic advantages. Nowadays, investiga-
tors planning a clinical trial have a wide range of sequen-
tial methods available to choose. These methods can be
categorized in two different types: boundaries approach
and repeated significance tests [1-6]. In this paper we have
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only considered boundaries approach, including triangu-
lar test (TT) and double triangular test (DTT), because of
their interesting properties [2,7-9]. Sebille and Bellissant
presented a nice account of the properties of TT and DTT
[7,8,10]. However, the properties of these methods, in
some cases, are still unknown. In particular, situations not
dealt with in previous articles are sequential designs with
unequal randomization ratios.
In a randomized controlled clinical trial with two treat-
ments, it is a standard practice to have approximately
equal-sized treatment groups since it maximizes the statis-
tical power for a given total sample size. However, there
are several research papers with topics on unequal rand-
omization that have demonstrated the efficiency of this
method in clinical trials [11-16]. They showed that in
some trials, which compare a new treatment against a
standard, using unequal randomization could be helpful
from the ethical and economic viewpoints. Yet there is no
consensus between ethicists and economists on the issue.
On the other hand, since sequential designs have ethical
and economic advantages per se, it seems reasonable to
use these methods when investigators decide to rand-
omize patients to the experimental and standard treat-
ment groups in unequal ratios.
Hence, the purpose of this study is to assess the effect of
unequal randomization on the statistical properties of TT,
DTT and SSD adjusted for unequal allocation ratio (SSD-
adj) by multiple simulation, and SSD using the formulas
used by Pocock [16]. In all of these methods the power
and average sample size numbers (ASNs) were computed
when the patients were allocated to the experimental and
standard treatments in different ratios.
Stopping boundaries based on the TT for α = 0.05, β = 0.05 and R = 1 with θR = 0.7 Figure 1
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Methods
We follow notations similar to that used by Sebille and
Bellissant [8]. Let θ be a measure of the difference between
the experimental and standard treatments. The clinical
trial can be viewed as a test of the null hypothesis of no
treatment difference H0 (θ = 0) against the alternative that
there is a difference H1 (θ ≠ 0). This parameter is designed
such that θ = 0 when treatments are equivalent, θ > 0 ( )
when the experimental treatment is better than the Stand-
ard one, and θ < 0 ( ) when the experimental treatment
is worse.
The trial considered here only involves the comparison of
two normally distributed responses in two-sided tests. We
defined the effect size as the difference between treat-
ments in units of standard deviation, θR = (µ2-µ1)/σ where
µ1 and µ2 are the means for the standard and experimental
groups, respectively, and σ is the common standard devi-
ation (σ1 = σ2 = σ).
Single stage design (SSD)
The traditional statistical approach in the analysis of clin-
ical trials is SSD with equal patients in each group. In this
method, the sample size is computed at the design phase
based on the significance level (α), difference of clinical
interest (θR), and power (1-β). In a two-group compara-
tive study where the response measure is normally distrib-
uted, the total sample size formula would be:
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Stopping boundaries based on the DTT for α = 0.05, β = 0.05 and R = 1 with θR = 0.7 Figure 2
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where   and Zα is the upper 100α% percen-
tile of N(0,1), that is, α = 1 - Φ(Zα). Z1-β is defined simi-
larly.
If NE and NS denote the numbers of patients assigned to
experimental and standard treatments with NE + NS = N
being fixed and   denotes the proportion on the
experimental treatment, then the power under H1 is given
by [16]:
In this formula Φ(·) denotes the cumulative function of
the standard normal distribution N(0,1).
However, if the investigator decides to allocate patients in
unequal ratio and aims to achieve the pre-specified
power, then the total sample size for SSD should be
adjusted by a factor dependent on the allocation ratio.
Therefore, the total sample size for SSDadj is equal to [2]:
where R is the ratio of patients in the experimental group
to the standard group or the reverse ratio.
Once the data have been collected, the statistical analysis
is conducted. Based on the SSD or SSDadj we cannot stop
an ongoing trial before inclusion of a predetermined sam-
ple size, even if the early data show a clear difference
between treatments.
Boundaries approach: triangular and double triangular 
tests (TT and DTT)
Sequential boundaries approach, the TT and DTT, permit
repeated statistical analyses to be performed throughout
the trial recruitment period in order to allow for early ter-
mination of a trial while maintaining a pre-specified α
and β level. This reduction in sample size has ethical and
economic advantages [8]. From the ethical viewpoint, this
reduction minimizes the number of patients who will be
given an inferior or ineffective treatment. Moreover, from
the economic viewpoint, it leads to saving in time and
resources. As shown in Figures 1 and 2, the TT and DTT are
based on the two-perpendicular axes [2,9]. These two axes
are two sample statistics that play particularly important
role in the investigation of θ and are fundamental to
sequential trials. The vertical axis is a cumulative measure
of the advantage of the experimental treatment, and will
be denoted by Z (efficient score for that calculated under
the null hypothesis). The horizontal axis, denoted by V,
indicates the amount of information about θ contained in
Z (Fisher's information) and it will increase as the trial
progresses [7]. The straight lines, the boundaries of the
tests, delineate a continuation and stopping region. The
equations of the straight line boundaries depend on the
values of the benefit to detect, and α and β, as well as on
the frequency of the analyses, defined in terms of the
number of patients included between two analyses [2]. At
each analysis, the two statistics V and Z are calculated
from all the data collected since the beginning of the study
and a point (V, Z) is defined on the sequential plan. The
consecutive points define a sample path from the left to
the right of the sequential plan. As long as the sample path
θ
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Table 1: ASN required to reach a conclusion under H0/H1, and when θ = θR/2 for the TT (R = 1), TT (R = 2), DTT (R = 1) and DTT (R = 
2) and sample size for the SSD (R = 1) and SSD (R = 2), for different values of θR, β (α = 0.05) and n = 12.
θR β SSD R = 1 SSD R = 2 TT(R = 1) TT(R = 2) DTT(R = 1) DTT(R = 2)
ASN (H0/H1)A S N  ( θR/2) ASN (H0/H1)A S N  ( θR/2) ASN (H0/H1)A S N  ( θR/2) ASN (H0/H1)A S N  ( θR/2)
0.4 0.05 325 366 168/185 239 188/208 269 220/184 247 248/208 273
0.1 263 296 135/164 191 152/184 215 179/165 199 201/185 224
0.5 0.05 208 234 108/120 155 122/134 173 143/120 159 160/135 179
0.1 168 189 88/107 124 98/120 139 116/108 129 129/120 145
0.6 0.05 144 163 77/85 109 86/95 122 100/86 112 113/95 125
0.1 117 131 62/76 87 69/85 98 82/76 90 92/85 102
0.7 0.05 106 119 57/64 81 64/71 91 75/64 84 84/72 93
0.1 86 97 47/57 65 52/64 73 61/57 68 68/64 76
0.8 0.05 81 91 45/50 63 50/56 70 59/50 65 63/56 71
0.1 66 74 37/45 51 41/50 57 46/44 51 53/50 59
0.9 0.05 64 72 36/41 51 40/45 56 46/41 51 52/45 58
0.1 52 58 30/37 41 33/41 46 39/37 42 43/41 48
1.0 0.05 52 58 30/34 42 34/38 47 39/35 43 44/38 48
0.1 42 47 25/31 34 28/34 38 29/29 32 36/34 39BMC Medical Research Methodology 2006, 6:1 http://www.biomedcentral.com/1471-2288/6/1
Page 5 of 8
(page number not for citation purposes)
stays within the two boundaries, the study is continued
and new patients are included. When the sample path
crosses one of the boundaries, the trial is stopped.
The triangular tests can be categorized in two classes based
on their power function. The power function, denoted by
C (θ), is defined as the probability that H0 is rejected when
the parameter θ is true. When the true treatment differ-
ence is θ, C+ (θ) and C- (θ) are the probability of reaching
the conclusion that the experimental treatment is signifi-
cantly better and worse than the standard, respectively.
Based on this definition two alternative power require-
ments will be specified: power requirement I and power
requirement II. TT is designed to satisfy power require-
ment I. In this situation C+(θR) = 1-β but no specification
is made for C- (-θR) and also C- (θR) is usually negligible.
On the other hand, DTT is designed to satisfy power
requirement II. In this situation, C+(θR) = C- (-θR) = 1-β
and both C+(-θR) and C- (θR) are negligible [2,17].
Simulation study
We studied the ASN for the TT and DTT by multiple sim-
ulations in PEST3 [17]. Our simulation design was very
similar to that used by Sebille and Bellissant [8]. For each
studied situation, we generated 30,000 independent com-
parative trials in which patient responses were drawn
from a normal distribution with mean µ1 (mean response
in standard group) equal to 10 and the standard deviation
equal to 5. The influences of different values of β and θR
(µ2) on the statistical properties of all tests were evaluated.
The total number of patients at each interim analysis (n)
was equal to 12. We also evaluated the influence of the
allocation ratio (R) on the statistical properties. R is
defined as the ratio of the patients in the experimental
group to the standard group. Namely, we chose two differ-
ent values for β(0.05 and 0.1), seven values for θR (0.4,
0.5, 0.6, 0.7, 0.8, 0.9 and 1.0), one value for n (n = 12)
and two values for R (1 and 2). The value of α was set to
0.05 for all simulated trials. We also calculated the
Sample size required by two-sided SSD and SSDadj and average sample number for the TT and the DTT (under ), for different  values of R, when n = 12, θR = 0.7 and β = α = 0.05 Figure 3
Sample size required by two-sided SSD and SSDadj and average sample number for the TT and the DTT (under  ), for differ-
ent values of R, when n = 12, θR = 0.7 and β = α = 0.05.
H1
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required sample size for SSD and SSDadj for the same val-
ues of θR, R, β and α as for TT and DTT by Formulas (1)
and (3), respectively. Moreover, we simulated the
required ASN and power for the TT (n = 12), DTT (n = 12),
and two-sided SSDadj for different values of R, when θR =
0.7 and β = α = 0.05. For SSD, the required sample size
and power were calculated for the same value of R, θR, α
and β using Formulas (1) and (2).
Results
Table 1 shows the ASN of patients required to reach a con-
clusion under H0, H1 and θ = θR/2 for different values of
θR and β for the SSD when R = 1, SSD when R = 2 (SSDadj),
TT when R = 1 and when R = 2, and DTT when R = 1 and
when R = 2. The ASNs under H0, H1 and θ = θR/2 were
smaller for all sequential tests than for SSD (R = 1), what-
ever values of θR, β and R were considered. Indeed, as
compared with the SSD (R = 1), there were decreases of
approximately 39% and 20% under H0, 29% and 28%
under H1, and 14% and 12% under θ = θR/2 in the ASNs
for the TT (R = 2) and DTT (R = 2), respectively. Moreover,
Table 1 shows that choosing R = 2 instead of R = 1
increases the sample size of SSD by approximately 12%
and the ASN of the TT and DTT by the same proportion
under H0, H1 and θ = θR/2. On the other hand, as com-
pared with SSD when R = 2 (SSDadj), there were decreases
of approximately 46% and 29% under H0, 37% and 36%
under H1, and 24% and 21% under θ = θR/2 in the ASNs
for the TT (R = 2) and DTT (R = 2), respectively.
Figure 3 displays the sample size required by the SSD and
the ASN for SSDadj, TT (n = 12) and DTT (n = 12) as a func-
tion of R when θR = 0.7 and β = 0.05. The ASN curves for
the TT and DTT under   always stayed beneath the sam-
ple size required by the SSDadj and were similar to one
another. Indeed, as compared with SSDadj, there were
decreases of approximately 39.5%, 39.5%, 40.4%, 41.5%,
42% and 42.7% in ASNs for TT and DTT when R was
equal to 1, 2, 3, 4, 5 and 9, respectively. Also, for R ≤ 4, the
ASN curves of the TT and DTT stayed beneath the sample
H1
+
Exact power for the SSD, and estimated power for the TT, the DTT (under ) and the SSDadj for different values of R, when n =  12, θR = 0.7 and β = α = 0.05 Figure 4
Exact power for the SSD, and estimated power for the TT, the DTT (under  ) and the SSDadj for different values of R, when 
n = 12, θR = 0.7 and β = α = 0.05.
H1
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size required by the SSD (N = 106). Indeed, as compared
with SSD, for R ≤ 4, they were decreased by approximately
39.5%, 32%, 21% and 8.5% in ASNs for TT and DTT
when R was equal to 1, 2, 3 and 4 respectively. On the
other hand, for R ≥ 2 the ASN curve of SSDadj remained
above the sample size required by SSD. Indeed, as com-
pared with SSD, they were increased by approximately
12.3%, 33%, 56.6%, 80% and 178% in ASNs for SSDadj
when R was equal to 2,3,4,5 and 9, respectively.
Figure 4 shows that in the SSD, with a fixed total sample
size, unequal randomization can lead to a reduction in
statistical power when the R increases. In contrast, for the
TT, DTT and SSDadj where there is no limit on patient
recruitment, the power curves remain constant.
Discussion
Sequential methods and unequal randomization design
are two different techniques in clinical trials, with their
ethical and economic advantages. However, no previous
study has combined unequal randomization with sequen-
tial analyses. In other words, the debates concerning une-
qual randomization were restricted to the SSD [11-16]
and sequential analyses were only discussed in situations
where the patients were equally randomized between the
treatment groups [7,8]. Sebille and Bellissant [8] showed
that, of the one-sided sequential tests, the one-sided TT (R
= 1) offers a substantial decrease in sample size compared
with the one-sided SSD (R = 1); namely 40% under H0
and H1 and 25% under θ = θR/2. In addition, they showed
that the two-sided TT (R = 1) offers a two-sided conclusion
with much fewer patients than the double TT (R = 1) and
two-sided SSD (R = 1), but at the expense of a high
decrease in power under  [7]. On the other hand,
according to Avins [13], Edwards [14] and Pocock [16],
unbalanced randomization has ethical advantages since
more patients are randomized to what is thought to be the
superior therapy. Also, Torgerson and Campbell [11,12]
showed that when research costs differ between treat-
ments and there is no constraint on total sample size, it is
more cost-effective to randomize more patients to the less
expensive treatment. However, Pocock [16] showed that,
when there is a ceiling on total sample size, unequal ran-
domization leads to a reduction in statistical power.
Hence, we expected that, in the practical situation, in
which the sample size of the SSD cannot be adjusted, the
TT (R = 2) and DTT (R = 2), compared with unadjusted
SSD, decrease the sample size while maintaining the
power of the trial to its planned value. As an important
result, our simulation study showed that even with the
maximum ASN which occurs at θ = θR/2, the TT (R = 2)
and DTT (R = 2) have smaller ASNs than the SSD (R = 1).
Also before the start of the work, we could not estimate
how much using R = 2 instead of R = 1 would increase the
sample size in the TT, DTT and SSD. However, based on
our findings, choosing R = 2 instead of R = 1 equally
increases the sample size in the sequential methods and
SSD up to 12%. Nevertheless, when the costs of the two
treatment groups are very different, allocation of more
patients to the cheaper treatment in the TT and DTT will
compensate for this increase rate in the sample size. This
decreases the total cost of the trial substantially.
However, it is necessary to present some characteristics of
our study. Firstly, to present a fair comparison, we have
only evaluated the statistical properties of the two-sided
TT and DTT under H0,   and  θR/2, because, under these
hypotheses, their power functions are identical [7]. Sec-
ondly, we did not compare the one-sided TT with other
two-sided tests simultaneously because it is quite contro-
versial in the literature [18,19].
Conclusion
This study shows that if we allocate patients unequally in
the SSD among the treatment groups and sample size ceil-
ing cannot be increased to maintain the power of the trial
due to economic restrictions, then an amalgamation of
the sequential analysis and unequal randomization, com-
pared with SSD, can be a compromise between statistical,
ethical and economic requirements.
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